Schrödinger, Inc.

Equities

SDGR

US80810D1037

Software

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
27 USD +1.39% Intraday chart for Schrödinger, Inc. -1.85% -24.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Citigroup Cuts Schrodinger Price Target to $39 From $47, Maintains Buy Rating MT
Goldman Sachs Cuts Schrodinger's Price Target to $26 From $29, Keeps Neutral Rating MT
Piper Sandler Cuts Price Target on Schrodinger to $50 From $60, Maintains Overweight Rating MT
Schrodinger's Q4 Adjusted Net Loss Narrows, Revenue Increases; Shares Down Pre-Bell MT
Transcript : Schrödinger, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (SDGR) SCHRODINGER Posts Q4 Revenue $74.1M, vs. Street Est of $79.1M MT
Schrödinger, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TD Cowen Starts Schrodinger With Outperform Rating, $42 Price Target MT
Sector Update: Health Care Stocks Ease Thursday Afternoon MT
Schrodinger Shares Rise as SGR-1505 Seen Well-tolerated in Early Trial; Three New Gene Mutation Programs Added MT
Transcript : Schrödinger, Inc. - Special Call
Schrodinger Says New Data Show 'Multiple Favorable Attributes' of Potential Leukemia Treatments MT
KeyBanc Initiates Schrodinger at Overweight With $38 Price Target, Cites 'Healthy Recurring Revenue Growth' in Software & Services, 'Attractive Valuation' MT
Morgan Stanley Trims Price Target on Schrodinger to $51 From $52, Maintains Equal-Weight Rating MT
Transcript : Schrödinger, Inc., Q3 2023 Earnings Call, Nov 01, 2023
Schrodinger Q3 Non-GAAP Loss Widens, Revenue Increases MT
Earnings Flash (SDGR) SCHRODINGER Posts Q3 Revenue $42.6M, vs. Street Est of $37.9M MT
Schrödinger, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BofA Securities Lowers Price Target on Schrodinger to $39 From $48, Maintains Neutral Rating MT
Copernic Catalysts, Inc. Announces Research Collaboration with Schrödinger, Inc. to Accelerate Sustainable Catalyst Discovery CI
Schrödinger, New York City College of Technology, and LaGuardia Community College Receives $1 Million Grant from the National Science Foundation to Increase Access to Computational Molecular Modeling Education CI
Transcript : Schrödinger, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 02:15 PM
Insider Sell: Schrodinger MT
Top Premarket Decliners MT
Transcript : Schrödinger, Inc., Q2 2023 Earnings Call, Aug 02, 2023
Chart Schrödinger, Inc.
More charts
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
27 USD
Average target price
37.7 USD
Spread / Average Target
+39.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Schrödinger, Inc. - Nasdaq
  4. News Schrödinger, Inc.
  5. Earnings Flash (SDGR) SCHRODINGER Reports Q1 Revenue $48.7M, vs. Street Est of $34.6M